BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24235083)

  • 1. Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure.
    Colussi G; Ganon L; Penco S; De Ferrari ME; Ravera F; Querques M; Primignani P; Holtzman EJ; Dinour D
    Nephrol Dial Transplant; 2014 Mar; 29(3):636-43. PubMed ID: 24235083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.
    Figueres ML; Linglart A; Bienaime F; Allain-Launay E; Roussey-Kessler G; Ryckewaert A; Kottler ML; Hourmant M
    Am J Kidney Dis; 2015 Jan; 65(1):122-6. PubMed ID: 25446019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis.
    Dinour D; Beckerman P; Ganon L; Tordjman K; Eisenstein Z; Holtzman EJ
    J Urol; 2013 Aug; 190(2):552-7. PubMed ID: 23470222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations.
    Carpenter TO
    J Steroid Biochem Mol Biol; 2017 Oct; 173():337-340. PubMed ID: 28093352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass.
    Ferraro PM; Minucci A; Primiano A; De Paolis E; Gervasoni J; Persichilli S; Naticchia A; Capoluongo E; Gambaro G
    Urolithiasis; 2017 Jun; 45(3):291-294. PubMed ID: 27639704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study.
    Cools M; Goemaere S; Baetens D; Raes A; Desloovere A; Kaufman JM; De Schepper J; Jans I; Vanderschueren D; Billen J; De Baere E; Fiers T; Bouillon R
    Bone; 2015 Dec; 81():89-96. PubMed ID: 26117226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A young girl with recurrent calculosis and hypercalcemia].
    Di Maio F; Vittori M; Bassi P; Fulignati P; D'Alonzo S; Ferraro PM
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait.
    Molin A; Baudoin R; Kaufmann M; Souberbielle JC; Ryckewaert A; Vantyghem MC; Eckart P; Bacchetta J; Deschenes G; Kesler-Roussey G; Coudray N; Richard N; Wraich M; Bonafiglia Q; Tiulpakov A; Jones G; Kottler ML
    J Clin Endocrinol Metab; 2015 Oct; 100(10):E1343-52. PubMed ID: 26214117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent hypercalcaemia associated with two pathogenic variants in the
    Leszczyńska D; Szatko A; Latocha J; Kochman M; Duchnowska M; Wójcicka A; Misiorowski W; Zgliczyníski W; Glinicki P
    Front Endocrinol (Lausanne); 2024; 15():1355916. PubMed ID: 38665259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect.
    O'Keeffe DT; Tebben PJ; Kumar R; Singh RJ; Wu Y; Wermers RA
    Osteoporos Int; 2016 Oct; 27(10):3121-5. PubMed ID: 27129455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?
    Brancatella A; Cappellani D; Kaufmann M; Borsari S; Piaggi P; Baldinotti F; Caligo MA; Jones G; Marcocci C; Cetani F
    J Clin Endocrinol Metab; 2021 Mar; 106(3):708-717. PubMed ID: 33249478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant Clinical Course of Vitamin-D-Hydroxylase (CYP24A1) Associated Hypercalcemia in Two Adult Brothers With Nephrocalcinosis.
    Jobst-Schwan T; Pannes A; Schlingmann KP; Eckardt KU; Beck BB; Wiesener MS
    Kidney Blood Press Res; 2015; 40(5):443-51. PubMed ID: 26304832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypercalcemia and inactive mutation of CYP24A1. Case-study and literature review].
    Seidowsky A; Villain C; Vilaine E; Baudoin R; Tabarin A; Kottler ML; Cavalier É; Souberbielle JC; Massy ZA
    Nephrol Ther; 2017 May; 13(3):146-153. PubMed ID: 28456639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations.
    Janiec A; Halat-Wolska P; Obrycki Ł; Ciara E; Wójcik M; Płudowski P; Wierzbicka A; Kowalska E; Książyk JB; Kułaga Z; Pronicka E; Litwin M
    Nephrol Dial Transplant; 2021 Jul; 36(8):1484-1492. PubMed ID: 33099630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlapping Phenotypes Associated With
    Molin A; Lemoine S; Kaufmann M; Breton P; Nowoczyn M; Ballandonne C; Coudray N; Mittre H; Richard N; Ryckwaert A; Lavillaureix A; Jones G; Bacchetta J; Kottler ML
    Front Endocrinol (Lausanne); 2021; 12():736240. PubMed ID: 34721296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.
    Nesterova G; Malicdan MC; Yasuda K; Sakaki T; Vilboux T; Ciccone C; Horst R; Huang Y; Golas G; Introne W; Huizing M; Adams D; Boerkoel CF; Collins MT; Gahl WA
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):649-57. PubMed ID: 23293122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
    Tebben PJ; Singh RJ; Kumar R
    Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal Hypercalcemia Due to Failure of 1,25-Dihydroxyvitamin-D3 Catabolism in a Patient With CYP24A1 Mutations.
    Shah AD; Hsiao EC; O'Donnell B; Salmeen K; Nussbaum R; Krebs M; Baumgartner-Parzer S; Kaufmann M; Jones G; Bikle DD; Wang Y; Mathew AS; Shoback D; Block-Kurbisch I
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2832-6. PubMed ID: 26097993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.